A Classification of Drug Substances According to Their Mechanism of Action REVIEW
Total Page:16
File Type:pdf, Size:1020Kb

Load more
Recommended publications
-
Neurotransmitter Resource Guide
NEUROTRANSMITTER RESOURCE GUIDE Science + Insight doctorsdata.com Doctor’s Data, Inc. Neurotransmitter RESOURCE GUIDE Table of Contents Sample Report Sample Report ........................................................................................................................................................................... 1 Analyte Considerations Phenylethylamine (B-phenylethylamine or PEA) ................................................................................................. 1 Tyrosine .......................................................................................................................................................................................... 3 Tyramine ........................................................................................................................................................................................4 Dopamine .....................................................................................................................................................................................6 3, 4-Dihydroxyphenylacetic Acid (DOPAC) ............................................................................................................... 7 3-Methoxytyramine (3-MT) ............................................................................................................................................... 9 Norepinephrine ........................................................................................................................................................................ -
A Simple Question... Histamine
A simple question... How was histamine discovered ? • by chemical synthesis … • from the analysis of plant extracts (ergot fungus Claviceps purpurea) • from the analysis of animal tissues extracts • through none of these approaches Antihistamines 21/03/2010 1 Histamine ... obtained by synthetic chemist in 1907 …as a chemical curiosity … detection of an identical compound in an extract from ergot fungus … and shown to cause a marked vasodilatation a similar effect is seen with tissues extracts produces a similar picture as a very severe allergic reaction recognized as a "biological" molecule (and not a product from putrefaction in 1927 ... Antihistamines 21/03/2010 2 1 From histidine to histamine ... HN HN CH CH NH 2 2 CH2 CH2 NH2 N COOH N L-histidine decarboxylase First inhibitor tritoqualine of histmine action … commercialized in France (HYPOSTAMINE ) Antihistamines 21/03/2010 3 Localization of histamine total blood leucocytes mastocytes 1. blood plasma other leucocytes 2. tissues ... the word comes from ("histos" = tissue !!) • skin • lung • gastrointestinal tract • central nervous system Antihistamines 21/03/2010 4 2 Actions of histamine • of capillary permability and vasodilatation cutaneous rednesses signs inflammation • bronchoconstriction important with the guinea-pig but under H2 retrocontol in man • of HCl secretion (pariteal cells of the stomach) • neurotransmission awakening reactions, tachycardia, hypertension nauseas, vomitting migraines neurological and comportmental signs Antihistamines 21/03/2010 5 Rappel: -
PACKAGE LEAFLET: INFORMATION for the USER Asacol® 800Mg MR Tablets (Mesalazine) Read All of This Leaflet Carefully Before You S
PACKAGE LEAFLET: INFORMATION FOR THE USER Asacol® 800mg MR tablets (mesalazine) Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. - If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. In this leaflet: 1. What Asacol 800mg MR tablets are and what they are used for 2. Before you take Asacol 800mg MR tablets 3. How to take Asacol 800mg MR tablets 4. Possible side effects 5. How to store Asacol 800mg MR tablets 6. Further information 1. WHAT ASACOL 800MG MR TABLETS ARE AND WHAT THEY ARE USED FOR Asacol 800mg MR tablets contain the active substance mesalazine (also known as 5- aminosalicylic acid) which is an anti-inflammatory drug used in the treatment of: • Ulcerative colitis - a disease of the large bowel (colon) and back passage (rectum) in which the lining of the bowel becomes inflamed (red and swollen). Symptoms can include rectal bleeding, frequent diarrhoea and abdominal pain. Asacol 800mg MR tablets act locally in the colon to reduce inflammation and can also prevent further episodes (flares) of ulcerative colitis. • Crohn’s ileo-colitis – a disease affecting the small bowel (terminal ileum) and colon in which the lining of the bowel becomes swollen and sore. -
Clinical Pharmacology 1: Phase 1 Studies and Early Drug Development
Clinical Pharmacology 1: Phase 1 Studies and Early Drug Development Gerlie Gieser, Ph.D. Office of Clinical Pharmacology, Div. IV Objectives • Outline the Phase 1 studies conducted to characterize the Clinical Pharmacology of a drug; describe important design elements of and the information gained from these studies. • List the Clinical Pharmacology characteristics of an Ideal Drug • Describe how the Clinical Pharmacology information from Phase 1 can help design Phase 2/3 trials • Discuss the timing of Clinical Pharmacology studies during drug development, and provide examples of how the information generated could impact the overall clinical development plan and product labeling. Phase 1 of Drug Development CLINICAL DEVELOPMENT RESEARCH PRE POST AND CLINICAL APPROVAL 1 DISCOVERY DEVELOPMENT 2 3 PHASE e e e s s s a a a h h h P P P Clinical Pharmacology Studies Initial IND (first in human) NDA/BLA SUBMISSION Phase 1 – studies designed mainly to investigate the safety/tolerability (if possible, identify MTD), pharmacokinetics and pharmacodynamics of an investigational drug in humans Clinical Pharmacology • Study of the Pharmacokinetics (PK) and Pharmacodynamics (PD) of the drug in humans – PK: what the body does to the drug (Absorption, Distribution, Metabolism, Excretion) – PD: what the drug does to the body • PK and PD profiles of the drug are influenced by physicochemical properties of the drug, product/formulation, administration route, patient’s intrinsic and extrinsic factors (e.g., organ dysfunction, diseases, concomitant medications, -
Histidine Decarboxylase Knockout Mice Production and Signal
Nitric Oxide Mediates T Cell Cytokine Production and Signal Transduction in Histidine Decarboxylase Knockout Mice This information is current as Agnes Koncz, Maria Pasztoi, Mercedesz Mazan, Ferenc of October 1, 2021. Fazakas, Edit Buzas, Andras Falus and Gyorgy Nagy J Immunol 2007; 179:6613-6619; ; doi: 10.4049/jimmunol.179.10.6613 http://www.jimmunol.org/content/179/10/6613 Downloaded from References This article cites 41 articles, 8 of which you can access for free at: http://www.jimmunol.org/content/179/10/6613.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on October 1, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2007 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Nitric Oxide Mediates T Cell Cytokine Production and Signal Transduction in Histidine Decarboxylase Knockout Mice1 Agnes Koncz,*† Maria Pasztoi,* Mercedesz Mazan,* Ferenc Fazakas,‡ Edit Buzas,* Andras Falus,*§ and Gyorgy Nagy2,3*¶ Histamine is a key regulator of the immune system. -
DESCRIPTION CLINICAL PHARMACOLOGY Mechanism Of
NDA 20-844/ Topamav Sprinkle Capsules Approved Labeling Text Version: 10/26/98 DESCRIPTION Topiramate is a sulfamate-substituted monosaccharide that is intended for use as an antiepileptic drug. TOPAMAX@ (topiramate capsules) Sprinkle Capsules are available as I5 mg, 25 mg and 50mg sprinkle capsules for oral administration as whole capsules or for opening and sprinkling onto soft food. Topiramate is a white crystalline powder with a bitter taste. Topiramate is most soluble in alkaline solutions containing sodium hydroxide or sodium phosphate and hawng a pH of 9 to IO. It is freely soluble in acetone, chloroform, dimethylsulfoxide, and ethanol. The solubility in water is 9.8 mg/mL. Its saturated solution has a pH of 6.3. Topiramate has the molecular formula C,,H,,NO,S and a molecular weight of 339.37. Topiramate is designated chemically as 2,3:4,5-Di-O-isopropylidene-~- D-fructopyranose sulfamate and has the following structural formula: H3C CH3 TOPAMAX” (topiramate capsules) Sprinkle Capsules contain topiramate coated beads in a hard gelatin capsule. The inactive ingredients are: sugar spheres (sucrose and starch), povidone, cellulose acetate, gelatin, silicone dioxide, sodium lauryl sulfate, titanium dioxide, and black pharmaceutical ink. CLINICAL PHARMACOLOGY Mechanism of Action: The precise mechanism by which topiramate exerts its antiseizure effect is unknown; however, electrophysiological and biochemical studies of the effects of topiramate on cultured neurons have revealed three properties that may contribute to topiramate’s antiepileptic efficacy. First, action potentials elicited repetitively by a sustained depolarization of the neurons are blocked by topiramate in a time-dependent manner, suggestive of a state-dependent sodium channel blocking action. -
Moving Beyond Single Gene-Drug Pairs in Clinical Pharmacogenomics Testing
Moving Beyond Single Gene-Drug Pairs in Clinical Pharmacogenomics Testing Yuan Ji, PhD, DABCP, FACMG Gwendolyn McMillin, PhD, DABCC Learning Objectives • Describe the strengths and limitations of pharmacogenomic testing. • List examples of single gene-drug associations with the strongest levels of evidence for clinical implementation. • Discuss cautions when considering the use of multi-gene drug associations to inform drug therapy decisions. 2 Disclosure • None 3 Outline • Singe gene-drug based pharmacogenomics (PGx) testing – An introduction – Evidence and examples – Considerations for developing and evaluating clinical PGx laboratory developed tests (LDTs) • Multi-gene PGx panels – Evidence and examples – PROs and CONs for utilizing PGx panels – Considerations for successful PGx implementation 4 Single Gene-Drug Based PGx Testing Yuan Ji, PhD, DABCP, FACMG Medical Director of Genomics and Genetics; PGx, ARUP Laboratories Associate Professor (Clinical) of Pathology, University of Utah Medications: Myths and Facts • are~30% peoplenot take“one at least-size one medication fits all” within a 30-day period • Most medications cause adverse drug events (ADEs) • Some medications like antibiotics may do more harm than good • CDC statistics: – ~ 200,000 ADEs-related ER visits in pediatric population (17 years or younger) – ~ 450,000 ADEs-related ER visits in older adults (65 years or older) – Medications, e.g., anticoagulant warfarin • Many ADEs are preventable by closely supervising of dosing, blood tests (therapeutic drug monitoring, TDM), -
In Vitro Pharmacology of Clinically Used Central Nervous System-Active Drugs As Inverse H1 Receptor Agonists
0022-3565/07/3221-172–179$20.00 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 322, No. 1 Copyright © 2007 by The American Society for Pharmacology and Experimental Therapeutics 118869/3215703 JPET 322:172–179, 2007 Printed in U.S.A. In Vitro Pharmacology of Clinically Used Central Nervous System-Active Drugs as Inverse H1 Receptor Agonists R. A. Bakker,1 M. W. Nicholas,2 T. T. Smith, E. S. Burstein, U. Hacksell, H. Timmerman, R. Leurs, M. R. Brann, and D. M. Weiner Department of Medicinal Chemistry, Leiden/Amsterdam Center for Drug Research, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands (R.A.B., H.T., R.L.); ACADIA Pharmaceuticals Inc., San Diego, California (R.A.B., M.W.N., T.T.S., E.S.B., U.H., M.R.B., D.M.W.); and Departments of Pharmacology (M.R.B.), Neurosciences (D.M.W.), and Psychiatry (D.M.W.), University of California, San Diego, California Received January 2, 2007; accepted March 30, 2007 Downloaded from ABSTRACT The human histamine H1 receptor (H1R) is a prototypical G on this screen, we have reported on the identification of 8R- protein-coupled receptor and an important, well characterized lisuride as a potent stereospecific partial H1R agonist (Mol target for the development of antagonists to treat allergic con- Pharmacol 65:538–549, 2004). In contrast, herein we report on jpet.aspetjournals.org ditions. Many neuropsychiatric drugs are also known to po- a large number of varied clinical and chemical classes of drugs tently antagonize this receptor, underlying aspects of their side that are active in the central nervous system that display potent effect profiles. -
Salofalk®) in an Open Study of 20 Patients with Ankylosing Spondylitis
Efficacy and Safety of Mesalazine (Salofalk®) in an Open Study of 20 Patients with Ankylosing Spondylitis J. CHRISTIAAN van DENDEREN, IRENE E. van der HORST-BRUINSMA, P. DICK BEZEMER, and BEN A.C. DIJKMANS ABSTRACT. Objective. Mesalazine (Salofalk®) was found to be effective and showed low toxicity in patients with inflammatory bowel disease. The association of gut lesions and spondyloarthropathy (SpA) is well known and we studied the efficacy and safety of a relatively high dose of mesalazine in patients with ankylosing spondylitis (AS). Methods. In an open study, mesalazine (3–4 g/day) was prescribed for 24 weeks to 20 patients (aged 18–70 yrs) with active AS, defined as the presence of at least one clinical criterion (morning stiff- ness > 30 min, peripheral synovitis, enthesopathy, or pain score > 2 on a visual analog scale of 10 cm) and one laboratory criterion [erythrocyte sedimentation rate (ESR) > 20 mm/h or C-reactive protein (CRP) > 20 mg/l]. Data on toxicity and disease activity variables (ESR, CRP, BASDAI, BASFI, BASMI, global assessment, and joint count) were obtained at baseline and after 4, 12, and 24 weeks, and analyzed on an intention-to-treat basis. Results. Study patients had a mean age of 41 years, with mean disease duration of 7.9 years and a mean ESR at baseline of 29 mm/h. After a mean of 9.3 weeks (range 2–22), 8 of the 20 patients prematurely stopped the medication because of adverse effects, mainly gastrointestinal complaints. Twelve patients completed the 24 weeks of the study using a mean dose of 3.2 g/day (range 1–4) mesalazine. -
United States Patent [191 [11] Patent Number: 5,696,273 Andre Et A]
USOO5696273A United States Patent [191 [11] Patent Number: 5,696,273 Andre et a]. [45] Date of Patent: Dec. 9, 1997 [54] METHOD FOR SYNTHESIZING OTHER PUBLICATIONS CUCURBITINE Pn'ce. Pathophysiology. Clinical Concepts of Disease Pro [75] Inventors: Patrice Andre. Neuvilles aux Bois; cess~ 19,36~ PP- 36-37- ‘ _ valérie Thiery_ Clery St Andre; Gémld Webster s New World Dictionary. 1988. p. 36. Guillaumet‘ 01-16mm an of France World Patents Index Latest. AN 87-32998? [47]. Derwent Publications Ltd.. London. GB. & JP. S. 62234013 (Osaka [73] Assignee: Parfums Christian Dior. Paris. France Yak'lhin Kmky) 14 Oct- 1937 Chemical Abstract. vol. 82. No. 23. 1975. p. 40. abstract _ 149446a. Pharmacological (anthelminthic) study of Cucur [21] APPL N°" 476’646 bita. ,A.E. Gonzalez a a1. [22] Filed; Jm 7, 1995 Scienta Sinica. vol. X. No. 7. 1961.T.-T. Sun et a1. “Chemi cal studies on cucurbita moschata duch". pp. 852-859. Related US. Application Data Journal of the Chemical Society. Chemical Communica tions. 1973. H]. Monteiro, “New synthesis of the ami [62] Division of Ser. No. 108,601 , ?led as PCT/FR92/00164 Feb. no-acid (+)-Cucurbitine”. p. 2. 24’ 1992, abandmed- Chemical and Pharmaceutical Bulletin. vol. 35. No. 9. Sep. [30] Foreign. Application. Pl'lol'lty. Data ..'. 5183;135:2149?' t.‘ nzym esandcatalsts.H.Pi y g Feb. 28, 1991 [FR] France ................................. .. 9102420 J. Fable. “Methoden der Organischen Chemie". vol. E5. Georg Thieme Verlag pp. 534-543. (1973). [5 .................... .. C071) 207/36 Derwent Publications Ltd. 52051033AN (Ogawa) 23 Apr.& 1977. [52] US. Cl. 548/531; 548/542; 548/550 world Patents Indcx Latest, 1937‘ AN 37473336 [39]_ [58] Field of Search 5481531. -
Immediately Dangerous to Life Or Health (IDLH) Value Profile: Butane
Butane CAS® No. 106-97-8 DEPARTMENT OF HEALTH AND HUMAN SERVICES Center for Disease Control and Prevention National Institute of Occupational Safety and Health This page intentionally left blank. Immediately Dangerous to Life or Health (IDLH) Value Profile Butane [CAS® No. 106-97-8] H3C CH3 DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention National Institute for Occupational Safety and Health This document is in the public domain and may be freely copied or reprinted. Disclaimer Mention of any company or product does not constitute endorsement by the National Institute for Occupational Safety and Health (NIOSH). In addition, citations to websites external to NIOSH do not constitute NIOSH endorsement of the sponsoring organizations or their programs or products. Furthermore, NIOSH is not responsible for the content of these websites. Ordering Information To receive this document or information about other occupational safety and health topics, contact NIOSH: Telephone: 1-800-CDC-INFO (1-800-232-4636) TTY: 1-888-232-6348 E-mail: [email protected] or visit the NIOSH ebsite at: www.cdc.gov/niosh For a monthly update on news at NIOSH, subscribe to NIOSH eNews by visiting www.cdc.gov/niosh/eNews. Suggested Citation NIOSH [2016]. Immediately dangerous to life or health (IDLH) value profile: butane. By Dotson GS, Maier A, Parker A, Haber L. Cincinnati, OH: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupa- tional Safety and Health, DHHS (NIOSH) Publication 2016-174. DHHS (NIOSH) Publication No. 2016-174 September 2016 ii IDLH Value Profile for Butane Foreword Chemicals are a ubiquitous component of the modern workplace. -
Development of Mesalazine Microspheres for Colon Targeting
International Journal of Applied Pharmaceutics ISSN- 0975-7058 Vol 9, Issue 4, 2017 Original Article DEVELOPMENT OF MESALAZINE MICROSPHERES FOR COLON TARGETING KATTA RAJESH, R. DEVESWARAN *, S. BHARATH, B. V. BASAVARAJ Department of Pharmaceutics, Faculty of Pharmacy, M. S. Ramaiah University of Applied Sciences, Bangalore 560054 Email: [email protected] Received: 28 Jan 2017, Revised and Accepted: 14 Jun 2017 ABSTRACT Objective: The present work was aimed at preparation of mesalazine microspheres by a non-aqueous solvent evaporation method using eudragit S 100 and eudragit L 100 as pH dependent polymers for colon targeting. Methods: The ratio of drug to polymer was varied and the effect of formulation variables revolutions per minute (RPM) (1000, 1500, 2000 and 2500) and concentration of span 80 (1%, 1.5%, 2% and 2.5%) were studied. Prepared microspheres were evaluated for particle size, percent drug entrapment, granular analysis, in vitro drug release studies, Fourier transformed infrared spectroscopy (FT-IR) Differential Scanning Calorimetry (DSC), X-ray diffraction (XRD) and scanning electron microscopy (SEM) studies. Results: Particle size has decreased and percent drug entrapment had increased with increase in RPM in all formulations. When the span 80 concentration increased, the particle size of the microsphere formulations increased and percent drug entrapment decreased in eudragit S 100 microspheres; whereas in eudragit L 100 microspheres, as the concentration of span 80 increased, the particle size of the microsphere formulations decreased. The prepared microspheres sustained the drug release over a period of 12 h. Conclusion: Thus eudragit S 100 and eudragit L 100 microspheres could constitute a promising approach for colon-specific and sustained delivery of mesalazine for the treatment of inflammatory bowel disease.